Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale E Johnson

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|November 25, 2018
Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal AntibodiesDale E Johnson
Expert Review of Clinical Pharmacology|November 25, 2011
Biotherapeutic first-in-human dose selection: making use of preclinical markersDale E Johnson
Expert Review of Clinical Pharmacology|March 12, 2013
Fusion of nonclinical and clinical data to predict human drug safetyDale E Johnson
Current Opinion in Drug Discovery & Development|January 5, 2010
Functional consequences of mTOR inhibitionSucha Sudarsanam, Dale E Johnson
Current Opinion in Drug Discovery & Development|January 20, 2009
Clustering and its application in multi-target predictionWilliam Liu, Dale E Johnson
Current Opinion in Drug Discovery & Development|February 1, 2006
Computational toxicology: heading toward more relevance in drug discovery and developmentDale E Johnson, Amie D Rodgers
Toxicology|April 17, 2002
Web resources for drug toxicityGrushenka H I Wolfgang, Dale E Johnson
Current Opinion in Drug Discovery & Development|February 3, 2007
Biomarkers: the pièce de résistance of innovative medicinesDale E Johnson, Dennis A Smith, B Kevin Park
Current Opinion in Drug Discovery & Development|January 20, 2009
Pharmacogenomics and adverse drug reactions; prospective screening for risk identificationDale E Johnson, Dennis A Smith, B Kevin Park
Current Opinion in Drug Discovery & Development|January 20, 2009
Current HIV therapeutics: mechanistic and chemical determinants of toxicityStephanie K Chiao, Donna L Romero, Dale E Johnson
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|November 25, 2018
Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal AntibodiesDale E Johnson
Expert Review of Clinical Pharmacology|November 25, 2011
Biotherapeutic first-in-human dose selection: making use of preclinical markersDale E Johnson
Expert Review of Clinical Pharmacology|March 12, 2013
Fusion of nonclinical and clinical data to predict human drug safetyDale E Johnson
Current Opinion in Drug Discovery & Development|January 5, 2010
Functional consequences of mTOR inhibitionSucha Sudarsanam, Dale E Johnson
Current Opinion in Drug Discovery & Development|January 20, 2009
Clustering and its application in multi-target predictionWilliam Liu, Dale E Johnson
Current Opinion in Drug Discovery & Development|February 1, 2006
Computational toxicology: heading toward more relevance in drug discovery and developmentDale E Johnson, Amie D Rodgers
Toxicology|April 17, 2002
Web resources for drug toxicityGrushenka H I Wolfgang, Dale E Johnson
Current Opinion in Drug Discovery & Development|February 3, 2007
Biomarkers: the pièce de résistance of innovative medicinesDale E Johnson, Dennis A Smith, B Kevin Park
Current Opinion in Drug Discovery & Development|January 20, 2009
Pharmacogenomics and adverse drug reactions; prospective screening for risk identificationDale E Johnson, Dennis A Smith, B Kevin Park
Current Opinion in Drug Discovery & Development|January 20, 2009
Current HIV therapeutics: mechanistic and chemical determinants of toxicityStephanie K Chiao, Donna L Romero, Dale E Johnson
Pageof 2